StockData

China SXT Pharmaceuticals, Inc. (SXTC) company profile

SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 1, 2026Score 4/30
$2.86−0.13 (-4.35%)

Close on Nov 17, 2026Market cap $2.74MP/E –Yield –

About China SXT Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

China SXT Pharmaceuticals, Inc. operates as a pharmaceutical company focused on traditional Chinese medicine pieces. Through its operating subsidiaries and variable interest entity, the company engages in the research, development, manufacture, and distribution of regular and advanced traditional Chinese medicine piece products. It also participates in tourism town development projects and related commercial activities. The company primarily markets and distributes its medicinal products to pharmaceutical clinics, hospitals, and commercial customers.

The company conducts its core business operations within the People's Republic of China and Hong Kong. Its operational footprint includes leased and owned facilities such as office spaces, warehouses, and specialized manufacturing equipment. Corporate operations and executive management are based at its principal executive offices located at 178 Taidong Road North in Taizhou, Jiangsu Province, China.

Summary of the business section of China SXT Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
China SXT Pharmaceuticals, Inc.
Headquarters
Taizhou, China
Address
178 Taidong Road North
Phone
8652386298290
Employees
56, Mar 31, 2026
Industry
Pharmaceutical Preparations
Incorporated in
D8
Fiscal year ends
March 31
Auditor
Enrome LLP, Singapore

Stock & identifiers

Ticker
SXTC
Exchange
Nasdaq
IPO date
Oct 3, 2018
Shares outstanding
1M, Mar 31, 2026
Filer category
Non-accelerated filer
Stock splits
1-for-80 reverse, Aug 10, 2026; 1-for-150 reverse, Feb 3, 2026; 1-for-25 reverse, Oct 5, 2023; 1-for-4 reverse, Aug 13, 2021; 1-for-4 reverse, Feb 22, 2021
SEC CIK
1723980
CUSIP
G2161P157
FIGI
BBG00JF23165
Share class FIGI
BBG00JF231Y4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Feng Felix ZhouCo-CEO and Director4
Xiaodong Sean PanChief Financial Officer–
Lim Sze Beng SimonCo-Chief Executive Officer–
Jun ZhengDirector–
Tong Tony LiuDirector–
Yong Lip CheeDirector–
Xiaodong JiDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 3, 2018
Offer price
$4.00
Exchange
Nasdaq
First trading day
Jan 4, 2019
First-day close
$5.74+43.5%
Lock-up ends (est.)
Jul 3, 2019

“The offering may terminate on (i) a date mutually acceptable to us and our Underwriter after which at least 2,500,000 Ordinary Shares are sold assuming an offering price of $4.00 per share (the minimum offering); (ii) such time as 3,750,000 Ordinary Shares are sold assuming an offering price of $4.00 per share (the maximum offering); (iii) such time that the maximum offering has been reached and all the Ordinary Shares under the over-subscription allo”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“had a total of 56 full-time employees and no part-time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?